Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma

NCT01712789 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT01712789
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01712789 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single-arm, Open-label Study With Pomalidomide in Combination With Low Dose Dexamethasone in Subjects With Refractory or Relapsed and Refractory Multiple Myeloma
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
November 6, 2012
Completion date
December 11, 2019
Enrollment
682 (actual)
Sites
112

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma